Clinical trial · Observational
Collection of Plasma Samples for Squamous Cell Carcinoma of the Head and Neck Patients
Prospective Collection of Plasma Samples From Patients Treated With Molecular Targeted Therapies for Squamous Cell Carcinoma of the Head and Neck
NCT02139020CI-TRIAL-00072123recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators will collect plasma samples at baseline, during treatment, and at progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Squamous Cell Carcinoma of the Head and Neck | Head and Neck Squamous Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Plasma samples | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- No treatment
- description
- Patients with squamous cell carcinoma of the head and neck, targeted therapies, plasma samples: * Group 1 = patients treated with radiation therapy and cetuximab according to Bonner et al \[11\] * Group 2 = patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. \[10\] * Group 3 = patients treated with a molecular targeted agent as a part of a clinical study
- interventionNames
- Other: Plasma samples
Primary outcomes (1)
- measure
- Prospective storage of plasma samples of patients treated with cetuximab or other targeted agents
- timeFrame
- one year after the collection
- description
- All the analyses will be done when we have enough of collected samples
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patients treated with radiation therapy and cetuximab according to Bonner et al * patients treated with cetuximab in combination with chemotherapy according to Vermorken et al. * patients treated with a molecular targeted agent as a part of a clinical study Exclusion Criteria: * patients with another type of head and neck cancer * patients non treated with targeted therapies
References
Publications (0)
Data not yet available
No reference posted for this study.